Press releases

Archive

May 25, 2023

Topas Therapeutics Initiates Phase 2a Clinical Trial for TPM502 in Celiac Disease; Appoints Chief Business Officer and Chief Operating Officer

February 15, 2022

Topas Therapeutics Appoints Cristina de Min, M.D. as Chief Medical Officer

July 29, 2021

Topas Therapeutics Extends Series B, Raising Total of €40 Million (~$ 48 Million) in this Round

Events

BIO International Convention

Boston, MA USA

June 5 – 8, 2023

To schedule a meeting, please use the BIO One-on-One Partnering System.

©2023 Topas Therapeutics. All rights reserved.